Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
Zacks Investment Research | May 21, 2019 09:50PM ET
Eli Lilly and Company (NYSE:LLY) announced that a phase II study evaluating its pipeline candidate mirikizumab in patients with moderately-to-severely active Crohn's disease (“CD”) met the primary and secondary endpoints.
Data from the phase II SERENITY study showed that treatment with mirikizumab led to significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. The data were presented at Digestive Disease Week medical conference in San Diego, CA. Lilly plans to begin phase III studies on mirikizumab in Crohn's disease later this year. Mirikizumab is already being evaluated in phase III studies in other immune diseases, psoriasis and ulcerative colitis.
Some popular drugs approved to treat Crohn's disease are AbbVie’s (NYSE:ABBV) Humira and UCB’s Cimzia, among others while several others like AbbVie’s newly approved psoriasis drug Skyrizi (risankizumab), Theravance Biopharma, Inc.’s (NASDAQ:TBPH) JAK inhibitor TD-1473 Galapagos and Gilead’s (NASDAQ:GILD) filgotinib and RedHill Biopharma Ltd RHB-104 are in late-stage studies for CD.
Immunology is a key therapeutic area for Lilly and its portfolio includes popular drug Taltz, which is marketed for the treatment of psoriasis and psoriatic arthritis. Meanwhile, regulatory applications seeking approval of Taltz for axial spondyloarthritis are also under review with the FDA. Lilly is also seeking to expand its immunology pipeline. In the first quarter, Lilly announced global licensing and research collaboration with two companies, ImmuNext, Inc. and Avidity Biosciences, Inc to make new medicines in immunology and autoimmune diseases.
Lilly’s shares have risen 0.7% this year so far against the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.